Briefing
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
In 173 patients from MITO16a/MaNGO-OV2a (393 plasma samples), post-surgical tumor fraction was detectable in 97% and, with fragmentomic profiles, was associated with PFS and OS independently of clinical covariates.
- Design: Evidence level 2
- Assay: Not named in the abstract